

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

MBHB00-919-D
250.111

09/630,846

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



RECEIVED

FEB 27 2002

TECH CENTER 1600/2900

Applicant:

Thompson

Filing Date:

8/2/2000

Group:

1635

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

KAL	1.	Cameron and Jennings, "Specific Gene Expression by Engineered Ribozymes in Monkey Cells," Proc. Natl. Acad. Sci. USA 86:9139-9143 (1989).
KAL	2.	Cushman et al., 1996, "Ribozyme Inhibition of VEGF-Mediated Endothelial Cell Proliferation in Cell Culture and VEGF-Induced Angiogenesis in a Rat Corneal Model" Abstract in IBC USA Conferences—Angiogenesis Inhibitors.
KAL	3.	Desjardins et al., "Pharmacokinetics of a Synthetic, Chemically Modified Hammerhead Ribozyme Against the Rat Cytochrome P-450 3A2 Mrna After Single Intravenous Injections," J. Pharmacology and Experimental Therapeutics 27(8):1419-1427 (1996)
KAL	4.	Efrat et al., "Ribozyme-mediated attenuation of pancreatic β -cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion," Proc. Natl. Acad. Sci. USA 91:2051-2055 (1994)
KAL	5.	Flory et al., "Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint," Proc. Natl. Acad. Sci. USA 93:754-758 (1996)
KAL	6.	Larsson et al., "Reduced β 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme," Nucleic Acids Research 22(12):2242-2248 (1994)
KAL	7.	Lieber and Kay, "Adenovirus-Mediated Expression of Ribozymes in Mice," Journal of Virology 70(5):3153-3158 (1996)
KAL	8.	Lyngstadaas et al., "A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo," EMBO J. 14:5224-5229 (1995)

EXAMINER	<i>Karen A. Jacobson</i>	DATE CONSIDERED
		05-07-02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.).

KAL	9.	Malone et al., "Cationic liposome-mediated RNA transfection", Proc. Nat. Acad. Sci. USA 86:6077 (1989).
KAL	10.	RPI Press Release, Aug. 29, 2001, http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=742975&TICK=RZYM&STORY=/www/story/08-29-2001/0001562763&EDATE=Aug+29,+2001 .
KAL PTE FEB 15 2002 PATENT & TRADEMARK OFFICE	11.	RPI Press Release, June 20, 2001, http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=742975&TICK=RZYM&STORY=/www/story/06-20-2001/0001517763&EDATE=Jun+20,+2001 .
KAL	12.	RPI Press Release, Oct. 8, 2001, http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=742975&TICK=RZYM&STORY=/www/story/10-08-2001/0001586793&EDATE=Oct+8,+2001 .
KAL	13.	Sambrook et al. (Molecular Cloning, A Laboratory Manual, 2nd ed., 1989, sections 16.30-32).
KAL	14.	Seachrist, Bioworld Today, January 15, 1997, at http://www.bioworld.com/bw/static.htm?path=br/data/bt01151997/bt01151997e.html
KAL	15.	Sioud, "Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor- α production by peritoneal cells in vitro and in vivo," Eur. J. Immunol. 26:1026-1031 (1996)
KAL	16.	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," Chemical Reviews 90:544-584 (1990).
KAL	17.	Yamamoto et al., "Abrogation of Lung Metastasis of Human Fibrosarcoma Cells by Ribozyme-Mediated Suppression of Integrin α 6 Subunit Expression," Int. J. Cancer 65:519-524 (1996)

RECEIVED
FEB 27 2002
TECH CENTER 1600/2900

EXAMINER	<i>Karen Giaconcius</i>	DATE CONSIDERED	<i>05-07-02</i>
----------	-------------------------	-----------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.